Endotoxin removal: how far from the evidence? The EUPHAS 2 Project

Area of Science:

• Critical Care Medicine
• Nephrology
• Infectious Diseases

Background:

• Polystyrene fiber cartridges with immobilized polymyxin B are used for extracorporeal hemoperfusion to remove circulating lipopolysaccharide (endotoxin) in septic patients.
• The EUPHAS Study (Early Use of Polymyxin B Hemoperfusion in Abdominal Septic Shock) provided initial randomized controlled trial evidence but had limitations including a small sample size.
• Italy is a primary user of polymyxin B hemoperfusion for sepsis, yet lacks structured data collection on its clinical effects.

Purpose of the Study:

• To establish a large, collaborative database for polymyxin B hemoperfusion treatments.
• To rigorously evaluate the efficacy and biological significance of endotoxin removal in clinical practice.
• To verify existing literature data, characterize treated patient populations, and identify potential patient subpopulations who may benefit most.

Main Methods:

• Prospective, multicentered, collaborative data collection study (EUPHAS 2).
• Focus on collecting comprehensive data on polymyxin B hemoperfusion treatments.
• Analysis will involve evaluating treatment efficacy, biological impact of endotoxin removal, and patient subgroup responses.

Main Results:

• Data collection is ongoing; results are pending.
• The study design aims to overcome limitations of previous trials by enrolling a larger, more diverse patient cohort.
• Anticipated outcomes include a clearer understanding of polymyxin B hemoperfusion's role in sepsis management.

Conclusions:

• EUPHAS 2 is designed to provide robust evidence on polymyxin B hemoperfusion for sepsis.
• The study seeks to enhance the understanding of endotoxin removal's clinical significance and optimize patient selection.
• Findings are expected to inform clinical practice and guide future research in sepsis treatment.